Table 1. Baseline characteristics of patients with metastatic colorectal cancer in two groups.
| Characteristic | mIFL group (n = 64) | Bevacizumab plus mIFL group (n = 139) |
| Sexa | ||
| Men | 36 (56.2) | 70 (50.4) |
| Women | 28 (44.8) | 69 (49.6) |
| Age (years)b | 50 (22–72) | 53 (23–77) |
| ECOG performance statusa | ||
| 0 | 23 (35.9) | 66 (47.5) |
| 1 | 41 (64.1) | 73 (52.5) |
| Primary tumor sitea | ||
| Colon | 31 (48.4) | 66 (47.5) |
| Rectum | 32 (50.0) | 66 (47.5) |
| Colorectum | 1 (1.6) | 7 (5.0) |
| Number of metastatic sitesa | ||
| 1 | 23 (35.9) | 58 (41.7) |
| >1 | 41 (64.1) | 81 (58.3) |
| Previous cancer therapya | ||
| Adjuvant chemotherapy | 25 (39.1) | 70 (50.4) |
| Radiotherapy | 12 (18.8) | 17 (12.2) |
ECOG, Eastern Cooperative Oncology Group; mIFL, modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion. aThe values are presented as number of patients, with the percentage in parentheses. bThe values are median age, with range in the parentheses.